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Abstract
Background
Blood groups are considered to have an impact on the occurrence and severity of coronavirus disease. While
among Chinese and Caucasian, blood group O individuals were less and group A were more likely to have
severe disease and mortality, data on South Asians aren’t available. 
Objective
This study aimed to find out the association of disease severity with blood group among coronavirus disease
2019 (COVID-19) patients.
Materials and methodology
Data were collected on a predesigned questionnaire containing details of patient demographics, medical
comorbidities, clinical presentation, and laboratory parameters. Multiple logistic regression was used to
determine the association of the blood group with the severity of coronavirus disease.
Result
Among the study participants, blood group B has the highest distribution (39.8%), followed by O (30.0), A
(21.9%), and AB (8.1%). About three-fourths (69.9%) had mild to moderate disease while 30.0% had severe
disease. Age, gender, hypertension, diabetes mellitus, and hemoglobin level were all associated with disease
severity among COVID-19 patients in univariate analysis on P-value for selection (<0.25). The final model
showed that the odds of disease severity is 3.62 times higher among males (OR: 3.62, 95% CI: 2.15-6.08) and
2.00 times higher among diabetic patients (OR: 2.00, 95% CI: 1.10-3.01) as compared to female and non-
diabetic respectively. However, there was no significant association found between blood group and disease
severity.
Conclusion
Blood groups don’t have any role in forecasting the severity of coronavirus disease. However, the male
gender and diabetics are prone to have severe disease.
Categories: Infectious Disease, Hematology
Keywords: disease severity, male gender, diabetes, covid-19, abo blood group
Introduction
On 31st December 2019, 27 cases of pneumonia of unidentified etiology were documented in Wuhan City,
Hubei province in China [1]. The causative agent was recognized from throat swab samples conducted by the
Chinese Centre for Disease Control and Prevention (CCDC) on 7th January 2020 and was later named severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was titled COVID-19 by the World
Health Organization (WHO) [2]. The novel coronavirus SARS-CoV-2, causing the novel coronavirus disease-
2019 (COVID-19), is currently spreading briskly worldwide; it has been recently declared as a pandemic by
WHO. Recent clinical observation advocates that patient age, male sex, and certain chronic medical
conditions (e.g., cardiovascular disease, diabetes, chronic obstructive pulmonary disease) appear to
represent a risk for the infection of SARS-Cov-2 and higher disease severity [3].
Evidence shows that blood groups have an impact on the occurrence and severity of coronavirus disease
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2019 (COVID-19). The vulnerability to viral infections has been previously found to be related to the ABO
blood group. For example, the Norwalk virus and Hepatitis B have clear blood group vulnerability [4,5]. It
was also reported that blood group O individuals were less likely to become infected by SARS coronavirus
[6]. Increased disease severity and high mortality are due to increased cardiovascular events in patients with
type A blood group and the fewer cardiovascular events in the type O blood group [7].
There is no literature relating blood groups with the predisposition and severity of COVID-19 from this part
of the world. Hence, this study is intended to study the relationship between the ABO blood types and
COVID-19 disease severity.
Materials And Methods
The study was designed based on the strobe guidelines. We conducted a retrospective study in tertiary care
hospital Karachi, data were collected from the in-patient’s medical record after obtaining permission from
the institutional ethical review committee of Aga Khan University Hospital (ERC#2020-5277-11810). All
adult patients (aged >18 years) diagnosed with COVID-19 using a nasopharyngeal swab run by PCR
technique, with a known blood group, were included in the study. While, COVID-19 cases with super-
imposed bacterial infections elicited by high pro-calcitonin levels, positive blood cultures, or labeled as
having bacterial infection by a consultant physician were excluded from the study. No patient identifiers
were recorded to protect patient’s privacy. A structured questionnaire was designed to collect information
regarding patient demographics, comorbid conditions, clinical presentation, disease severity, and laboratory
parameter. Disease severity was characterized as per World Health Organization into non-severe, severe,
and critical disease [8].
Trained research staff collected the data based on the inclusion criteria and completed all patients’
information on pre-designed performa. A total of 369 patients of COVID-19 with known blood groups were
included within the period of three months (1st April-30th June 2020).
Results
Our study included 369 patients of COVID-19, of which 57.4% (n=212) were male and remaining 42.5% (n =
157) were females. The mean (± SD) age in years of the study participant was 52.8 ± 17.7. Almost 30.0% of
patients have greater disease severity while 69.9% have a non-severe disease. Blood group B has the highest
distribution (39.8%) among COVID-19 infected patients followed by O (30.0), A (21.9%), and AB (8.1%).
Besides, the prevalence of other comorbidities, documenting hypertension as 38.7%, diabetes mellitus as
36.8%, ischemic heart disease as 15.1%, lung disease as 5.6%, and chronic kidney disease as 10.0% (Table 1). 
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Characteristics n (%)




Blood group  
A 81 (21.9)
B 147 (39.8)
O 111 (30.0) 
AB 30 (8.1)
Hypertension (HTN)  
No 226 (61.2)
Yes 143 (38.7)
Diabetes mellitus (DM)  
No 233 (63.1)
Yes 136 (36.8)
Ischemic heart disease (IHD)  
No 313 (84.8)
Yes 56 (15.1)
Lung disease  
No 348 (94.3)
Yes 21 (5.6)
Chronic kidney disease (CKD)  
No 332 (89.9)
Yes 37 (10.0)
Disease severity  
No 258 (69.9)
Yes 111 (30.0)
Hemoglobin level (Hb), mean ± SD  11.7 ± 2.6
TABLE 1: Basic characteristics of study participants (N = 369).
All independent variables were considered for their potential association with disease severity in univariate
analysis using logistic regression for which unadjusted Odds Ratios were calculated. Age, gender,
hypertension, diabetes mellitus, and hemoglobin level, were all associated with disease severity among
COVID-19 patients in univariate analysis on P-value for selection (< 0.05) as mentioned in Table 2 
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Characteristics OR (95% CI) P-value
Age (years) 1.04 (1.02-1.05) <0.001*
Gender   
Males 3.85 (2.30-6.44) <0.001*
Females -  
Blood group   
A 1.11 (0.60-2.07)  
B 0.88 (0.51-1.52) 0.55
O 1.57 (0.68-3.63)  
AB -  
Hypertension (HTN)   
No -  
Yes 1.61 (1.02-2.54) 0.037*
Diabetes mellitus (DM)   
No -  
Yes 1.91 (1.22-3.03) 0.004*
Ischemic heart disease (IHD)   
No -  
Yes 1.94 (1.08-3.49) 0.027
Lung disease   
No -  
Yes 1.46 (0.58-3.63) 0.419
Chronic kidney disease (CKD)   
No -  
Yes 0.72 (0.33-1.59) 0.412
Hemoglobin level (Hb) 1.15 (1.05-1.27) 0.001*
TABLE 2: Univariate analysis of factors associated with disease severity among COVID-19
patients of Karachi, Pakistan (N = 369).
OR, odds ratio; CI, confidence interval. *P-value of ≤0.05 was considered statistically significant.
The findings from multiple logistic regression models are given in Table 3, examining the association
between disease severity and the blood group. The final model showed that the odds of disease severity
among male patients are 3.62 times greater than female patients (OR: 3.62, 95% CI: 2.15-6.08). Moreover, the
odds of disease severity are 2.00 times higher among diabetic patients than non-diabetic patients (OR: 2.00,
95% CI: 1.10-3.01). However, there was no significant association found between blood group and disease
severity among COVID-19 patients. 
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Characteristics OR (95% CI) P-value
Gender   
Males 3.62 (2.15-6.08) <0.001*
Females -  
Blood group   
A 1.18 (0.61-2.26) 0.611
B 0.86 (0.48-1.53) 0.615
O - -
AB 1.48(0.61-3.58) 0.380
Diabetes mellitus (DM)   
No -  
Yes 2.00 (1.10-3.01) 0.018*
TABLE 3: Multivariable analysis of factors associated with disease severity among COVID-19
patients of Karachi, Pakistan (N = 369).
*P-value of ≤0.05 was considered statistically significant.
Discussion
In this observational study, we found that COVID-19 disease severity is not associated with any of the ABO
blood group types, and the same observations were also found in other studies [9,10]. However, in several
studies, it has been found that people with blood A suffer more severe disease as compared to the individual
with blood group O [11,12]. The proposed mechanism for higher disease severity in the individual with blood
group A includes its positive association with angiotensin-converting enzyme activity and higher expression
of adhesion molecules which in turn increase inflammation and hinders circulation [11].
Zhao et al. found that ABO blood groups play role in predisposing the people with blood group A to acquire
the disease as opposed to the individual with blood group O [13], but in our study, the blood group B people
were predominant that is 39.8% while people from group A were 21% only. The possible reason could be that
we included only those patients whose blood groups were already known for some other reasons like blood
donation and the different ethnicity of our study population as it does have a role in ABO blood typing [14].
Moreover, almost one-third of our study participants were having a non-severe disease (69.9%) while only
21.9% had severe disease.
Male gender was strongly correlated with disease severity in our study population, congruent to already
established evidence [15]. The factors responsible for less severe disease in females include their lower
proneness to disease as they are equipped with two copies of the X chromosome which bears the genes
involved in the regulation of innate immunity. They also have higher expression toll-like receptors-7 (TLR7)
and CD4+ lymphocytes which play a key role in the defense against viral infection and the clearance of
viruses respectively [16].
We also found that diabetic patients were having more severe COVID-19 disease as compared to their
counterparts [17]; possible reasons include the metabolic changes in diabetic patients, chronic
inflammation, attenuation of both innate and adaptive immune responses predisposing to secondary
infection [18]. Moreover, diabetic patients have a higher expression of angiotensin-converting enzyme 2,
which facilitates viral uptake thereby increase chances of having severe disease than non-diabetic patients
[19,20].
The findings of our study are important; however, it was a small observation single-center study, so the
findings can't be generalized. Studies conducted in multiple centers on diverse populations will help in
establishing the relationship of ABO blood groups with COVID-19 disease severity 
Conclusions
 We found no association between blood groups and COVID-19 disease severity. However, male gender and
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diabetes mellitus were strongly associated with disease severity, warranting more vigilant care.
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